[Current status, issues, and optimization strategies for quality control in the diagnosis and treatment of thyroid cancer in China].

As a pivotal disease entity in implementing the "Healthy China 2030" strategy, thyroid cancer necessitates the establishment of a quality control system that exemplifies cancer prevention and treatment. This study deconstructs systemic deficiencies across five critical dimensions under national thyroid cancer quality control standards: controversies in surgical standardization and lymph node dissection scope, absence of dynamic evaluation frameworks for ¹³¹I therapy, inadequate risk management in thyroid-stimulating hormone (TSH) suppression therapy, heterogeneity in ultrasound morphological interpretation, and lagging integration of standardized pathological diagnosis with informatics. To address these challenges, the current article proposes a strategic framework encompassing standardized surgical protocols, innovative dynamic assessment models for ¹³¹I therapy, stratified TSH suppression targets with risk-alert thresholds, standardized ultrasound radiomics feature acquisition systems, and intelligent pathology-assisted diagnostic platforms. Through synergistic advancement in clinical standardization, technological innovation, and digital intelligence integration, this multidimensional system achieves dual objectives of homogenized diagnostic-therapeutic quality and improved survival outcomes. Specifically, it establishes an innovative paradigm for quality control in malignant tumor management, facilitating the translation of the"Healthy China 2030"strategy from policy formulation to clinical implementation.